Australia’s EpiPen shortage is officially over, nearly nine months after manufacturing problems saw the devices disappear from pharmacy shelves.

The TGA says it has received confirmation that supply issues affecting EpiPen 300µg adrenaline have now been sufficiently resolved and there are now enough of the auto-injectors in pharmacies to meet demand from patients.

Imports of EpiPens, which are the only 300µg adrenaline auto-injectors on the PBS, first began falling short last April, meaning patients were not always able to access the devices immediately in all pharmacies.

The device’s supplier, Mylan Australia, blamed the delays on issues with manufacturer Meridian Medical Technologies, which Mylan said had also led to a shortage of EpiPen Junior in 2017.